e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

114.39 +0.10 (+0.09%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 26, 2022

Gainers

Via Benzinga

73 Biggest Movers From Yesterday ↗

May 17, 2022

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.

Via Benzinga

Expert Ratings for Arcellx ↗

May 13, 2022

Analysts have provided the following ratings for Arcellx (NASDAQ:ACLX) within the last quarter:

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

March 11, 2022

During Friday's session, 198 companies made new 52-week lows. Key Facts About Today's 52-Week Highs And Lows: Alibaba Group Holding (NYSE:BABA) is the largest...

Via Benzinga

CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19 ↗

February 04, 2022

CAR-T company Arcellx Inc (NASDAQ: ACLX) priced its IPO at

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 17, 2022

On Tuesday, 123 stocks made new 52-week lows.

Via Benzinga

Arcellx, Inc To Start Trading Tomorrow ↗

February 03, 2022

ARCELLX, INC (NASDAQ:ACLX) IPO will take place February, 04 on the NASDAQ exchange under the ticker ACLX. The company is offering shares at an expected price between $15.00 and $...

Via Benzinga

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma ↗

May 10, 2022

Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 30, 2022

On Wednesday, 29 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

March 31, 2022

On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

Opening Day: AN2 Therapeutics Rises In Public Debut After Upsized IPO ↗

March 26, 2022

Shares of AN2 Therapeutics rose over 15% in its trading debut on Friday following an upsized initial public offering. This was only the second initial public offering this month, as the IPO market...

Via Talk Markets

Stocks That Hit 52-Week Lows On Tuesday ↗

March 22, 2022

Tuesday's session saw 52 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 21, 2022

During Monday's session, 39 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap to set a...

Via Benzinga

BofA Initiates Arcellx With Buy On Its Novel Therapy Approach ↗

March 01, 2022

Arcellx (NASDAQ: ACLX) is advancing into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Hanesbrands And 2 Other Stocks Bought By Insiders ↗

February 11, 2022

US stock futures traded lower this morning after recording sharp losses in the previous session. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Insiders Buy Over $43M Of 4 Stocks ↗

February 10, 2022

US stock futures traded mixed this morning ahead of the inflation data due today. Investors, meanwhile, focused on some notable insider trades

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

February 07, 2022

On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in terms of market cap to set a new 52-week low. OceanPal (...

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

Opening Day: Arcellx Raises $124M In Wall Street Debut ↗

February 05, 2022

Cell therapy biotech Arcellx made its public debut on Friday, raising $124 million to bankroll its multiple myeloma CAR-T study.

Via Talk Markets

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy